Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Cisplatin administration & dosage"" wg kryterium: Temat


Tytuł :
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
Autorzy :
Manara, Maria Cristina
Valente, Sergio
Cristalli, Camilla
Nicoletti, Giordano
Landuzzi, Lorena
Zwergel, Clemens
Mazzone, Roberta
Stazi, Giulia
Arimondo, Paola
Pasello, Michela
Guerzoni, Clara
Picci, Piero
Nanni, Patrizia
Lollini, Pier-Luigi
Mai, Antonello
Scotlandi, Katia
Pokaż więcej
Temat :
MESH: Animals
MESH: Osteosarcoma/drug therapy
MESH: Osteosarcoma/metabolism
MESH: Quinolines/chemistry
MESH: Male
MESH: DNA (Cytosine-5-)-Methyltransferase 1/genetics
MESH: Antineoplastic Combined Chemotherapy Protocols/therapeutic use
DNA Methyltransferase Inhibitor
MESH: Osteosarcoma/genetics
MESH: Aminoquinolines/pharmacology
MESH: Tumor Burden/genetics
chemotherapy
epigenetics
MESH: Aminoquinolines/administration & dosage
MESH: Doxorubicin/administration & dosage
MESH: Enzyme Inhibitors/chemistry
[SDV.CAN]Life Sciences [q-bio]/Cancer
MESH: Bone Neoplasms/drug therapy
MESH: Enzyme Inhibitors/administration & dosage
MESH: Enzyme Inhibitors/pharmacology
MESH: Xenograft Model Antitumor Assays
MESH: Bone Neoplasms/genetics
MESH: Benzamides/pharmacology
MESH: Tumor Burden/drug effects
MESH: Cisplatin/administration & dosage
MESH: Humans
MESH: Bone Neoplasms/metabolism
DNA methylation
MESH: Gene Expression Regulation, Neoplastic/drug effects
patient-derived xenograft (PDX)
MESH: Mice, Knockout
MESH: DNA (Cytosine-5-)-Methyltransferase 1/antagonists & inhibitors
MESH: DNA (Cytosine-5-)-Methyltransferase 1/metabolism
MESH: Benzamides/administration & dosage
[CHIM.THER]Chemical Sciences/Medicinal Chemistry
osteosarcoma
MESH: Cell Line, Tumor
Źródło :
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2018, 17 (9), pp.1881-1892. ⟨10.1158/1535-7163.MCT-17-0818⟩
Opis pliku :
STAMPA
Tytuł :
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
Autorzy :
Manara, Maria Cristina
Valente, Sergio
Cristalli, Camilla
Nicoletti, Giordano
Landuzzi, Lorena
Zwergel, Clemens
Mazzone, Roberta
Stazi, Giulia
Arimondo, Paola
Pasello, Michela
Guerzoni, Clara
Picci, Piero
Nanni, Patrizia
Lollini, Pier-Luigi
Mai, Antonello
Scotlandi, Katia
Pokaż więcej
Temat :
MESH: Aminoquinolines/administration & dosage
MESH: Aminoquinolines/pharmacology
MESH: Cisplatin/administration & dosage
MESH: DNA (Cytosine-5-)-Methyltransferase 1/antagonists & inhibitors
MESH: DNA (Cytosine-5-)-Methyltransferase 1/genetics
MESH: DNA (Cytosine-5-)-Methyltransferase 1/metabolism
MESH: Doxorubicin/administration & dosage
MESH: Enzyme Inhibitors/administration & dosage
MESH: Enzyme Inhibitors/chemistry
MESH: Enzyme Inhibitors/pharmacology
MESH: Gene Expression Regulation, Neoplastic/drug effects
MESH: Humans
MESH: Animals
MESH: Male
MESH: Mice, Knockout
MESH: Osteosarcoma/drug therapy
MESH: Osteosarcoma/genetics
MESH: Osteosarcoma/metabolism
MESH: Quinolines/chemistry
MESH: Tumor Burden/drug effects
MESH: Tumor Burden/genetics
MESH: Xenograft Model Antitumor Assays
MESH: Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MESH: Benzamides/administration & dosage
MESH: Benzamides/pharmacology
MESH: Bone Neoplasms/drug therapy
MESH: Bone Neoplasms/genetics
MESH: Bone Neoplasms/metabolism
MESH: Cell Line, Tumor
[CHIM.THER]Chemical Sciences/Medicinal Chemistry
[SDV.CAN]Life Sciences [q-bio]/Cancer
Źródło :
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2018, 17 (9), pp.1881-1892. ⟨10.1158/1535-7163.MCT-17-0818⟩
Tytuł :
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Autorzy :
de Boer, Stephanie M.
Powell, Melanie E.
Mileshkin, Linda
Katsaros, Dionyssios
Bessette, Paul
Haie-Meder, Christine
Ottevanger, Petronella B.
Ledermann, Jonathan A.
Khaw, Pearly
Colombo, Alessandro
Fyles, Anthony
Baron, Marie Helene
Jürgenliemk-Schulz, Ina M.
Kitchener, Henry C.
Nijman, Hans W.
Wilson, Godfrey
Brooks, Susan
Carinelli, Silvestro
Provencher, Diane
Hanzen, Chantal
Lutgens, Ludy C.H.W.
Smit, Vincent T.H.B.M.
Singh, Naveena
Do, Viet
D'Amico, Romerai
Nout, Remi A.
Feeney, Amanda
Verhoeven-Adema, Karen W.
Putter, Hein
Creutzberg, Carien L.
McCormack, Mary
Whitmarsh, Karen
Allerton, Rozenn
Gregory, Deborah
Symonds, Paul
Hoskin, Peter J.
Adusumalli, Madhavi
Anand, Anjana
Wade, Robert
Stewart, Alexandra
Taylor, Wendy
Kruitwagen, Roy F.P.M.
Hollema, Harry
Pras, Elizabeth
Snyers, An
Stalpers, Lukas
Jobsen, Jan J.
Slot, Annerie
Mens, Jan Willem M.
Stam, Tanja C.
Pokaż więcej
Temat :
Carboplatin/administration & dosage
no
Comparative Study
Neoplasm Staging
Cisplatin/administration & dosage
Oncology
Carcinoma, Endometrioid/mortality
Paclitaxel/administration & dosage
Research Support, Non-U.S. Gov't
New Zealand
Neoplasm Grading
Time Factors
Endometrial Neoplasms/mortality
Dose Fractionation, Radiation
Female
Europe
Risk Factors
Chemoradiotherapy, Adjuvant/adverse effects
Aged
Australia
Middle Aged
Treatment Outcome
Clinical Trial, Phase III
Randomized Controlled Trial
Gynecologic Surgical Procedures/adverse effects
Lymph Node Excision
Canada
Multicenter Study
Journal Article
Radiotherapy, Adjuvant
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Humans
Źródło :
PORTEC study group 2018, ' Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 3, pp. 295-309 . https://doi.org/10.1016/S1470-2045(18)30079-2
lancet oncology, 19(3), 295 - 309. Lancet Publishing Group
The Lancet Oncology, 19(3), 295. Lancet Publishing Group
Opis pliku :
image/pdf
Tytuł :
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Autorzy :
de Boer, Stephanie M.
Powell, Melanie E.
Mileshkin, Linda
Katsaros, Dionyssios
Bessette, Paul
Haie-Meder, Christine
Ottevanger, Petronella B.
Ledermann, Jonathan A.
Khaw, Pearly
Colombo, Alessandro
Fyles, Anthony
Baron, Marie-Helene
Jurgenliemk-Schulz, Ina M.
Kitchener, Henry C.
Nijman, Hans W.
Wilson, Godfrey
Brooks, Susan
Carinelli, Silvestro
Provencher, Diane
Hanzen, Chantal
Lutgens, Ludy C. H. W.
Smit, Vincent T. H. B. M.
Singh, Naveena
Do, Viet
D'Amico, Romerai
Nout, Remi A.
Feeney, Amanda
Verhoeven-Adema, Karen W.
Putter, Hein
Creutzberg, Carien L.
Pokaż więcej
Temat :
Carboplatin/administration & dosage
Neoplasm Staging
Cisplatin/administration & dosage
GYNECOLOGIC-ONCOLOGY-GROUP
CHEMOTHERAPY
Paclitaxel/administration & dosage
Carcinoma, Endometrioid/mortality
New Zealand
Neoplasm Grading
Time Factors
Endometrial Neoplasms/mortality
CLINICAL-TRIALS
Dose Fractionation, Radiation
Female
Europe
Risk Factors
Chemoradiotherapy, Adjuvant/adverse effects
Aged
Australia
Middle Aged
PROGNOSIS
Treatment Outcome
Article
RECURRENCE
RADIATION-THERAPY
III TRIAL
Gynecologic Surgical Procedures/adverse effects
Lymph Node Excision
CARCINOMA PATIENTS
Canada
QUALITY-OF-LIFE
Radiotherapy, Adjuvant
STAGE-I
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Humans
Źródło :
Lancet oncology, 19(3), 295 - 309. Elsevier Science
Lancet Oncology, 19(3), 295 - 309. ELSEVIER SCIENCE INC
Opis pliku :
application/pdf
Tytuł :
Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)
Autorzy :
Beier, Dagmar
Proescholdt, Martin
Reinert, Christiane
Pietsch, Torsten
Jones, David T W
Pfister, Stefan M
Hattingen, Elke
Seidel, Clemens
Dirven, Linda
Luerding, Ralf
Reijneveld, Jaap
Warmuth-Metz, Monika
Bonsanto, Matteo
Bremer, Michael
Combs, Stephanie E
Rieken, Stefan
Herrlinger, Ulrich
Kuntze, Holger
Mayer-Steinacker, Regine
Moskopp, Dag
Schneider, Thomas
Beringer, Andreas
Schlegel, Uwe
Stummer, Walter
Welker, Helmut
Weyerbrock, Astrid
Paulsen, Frank
Rutkowski, Stefan
Weller, Michael
Wick, Wolfgang
Kortmann, Rolf-Dieter
Bogdahn, Ulrich
Hau, Peter
Pokaż więcej
Temat :
Craniospinal Irradiation
Chemotherapy, Adjuvant
Vincristine/administration & dosage
Cisplatin/administration & dosage
Young Adult
Lomustine/administration & dosage
Pilot Projects
Feasibility Studies
Survival Rate
Female
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
cognition
Medulloblastoma/pathology
b_open_article_in_toll_access_journal
medulloblastoma
Clinical Investigations
Chemoradiotherapy
health-related quality of life
Middle Aged
imaging
Prognosis
Follow-Up Studies
radiochemotherapy
Prospective Studies
Journal Article
Cerebellar Neoplasms/pathology
Adult
Humans
Male
Źródło :
Dagmar, D, Proescholdt, M, Reinert, C, Pietsch, T, Jones, D T W, Pfister, S M, Hattingen, E, Seidel, C, Dirven, L, Luerding, R, Reijneveld, J, Warmuth-Metz, M, Bonsanto, M, Bremer, M, Combs, S, Rieken, S, Herrlinger, U, Kuntze, H, Mayer-Steinacker, R, Moskopp, D, Schneider, T, Beringer, A, Schlegel, U, Stummer, W, Welker, H, Weyerbrock, A, Paulsen, F, Rutkowski, S, Weller, M, Wick, W, Kortmann, R-D, Bogdahn, U & Hau, P 2018, ' Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) ', Neuro-Oncology, vol. 20, no. 3, pp. 400–410 . https://doi.org/10.1093/neuonc/nox155
Neuro-Oncology, 20(3), 400 - 410. Oxford University Press
Opis pliku :
application/pdf
Tytuł :
Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy:a dose-escalation study
Autorzy :
Herrstedt, Jørn
Summers, Yvonne
Daugaard, Gedske
Christensen, Thomas B.
Holmskov, Karin
Taylor, Paul D.
Fox, Gabriel M.
Molassiotis, Alexander
Pokaż więcej
Temat :
Adult
Aged
Amisulpride
Antiemetics/therapeutic use
Cisplatin/administration & dosage
Dopamine Antagonists/therapeutic use
Female
Humans
Male
Middle Aged
Nausea/chemically induced
Ondansetron/therapeutic use
Remission Induction
Serotonin 5-HT3 Receptor Antagonists/therapeutic use
Sulpiride/analogs & derivatives
Vomiting/chemically induced
Źródło :
Herrstedt, J, Summers, Y, Daugaard, G, Christensen, T B, Holmskov, K, Taylor, P D, Fox, G M & Molassiotis, A 2018, ' Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy : a dose-escalation study ', Supportive Care in Cancer, vol. 26, no. 1, pp. 139–145 . https://doi.org/10.1007/s00520-017-3825-2
Tytuł :
Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study
Autorzy :
van Gelder, M.
van Oers, M. H.
Alemayehu, W. G.
Abrahamse-Testroote, M. C. J.
Cornelissen, J. J.
Chamuleau, M. E.
Zachée, P.
Hoogendoorn, M.
Nijland, M.
Petersen, E. J.
Beeker, A.
Timmers, G.-J.
Verdonck, L.
Westerman, M.
de Weerdt, O.
Kater, A. P.
Pokaż więcej
Temat :
Transplantation Conditioning/methods
Neoplasm, Residual
Disease-Free Survival
Hematopoietic Stem Cell Transplantation/methods
Cisplatin/administration & dosage
Survival Rate
Risk
Middle Aged
Leukemia, Lymphocytic, Chronic, B-Cell/mortality
Humans
Treatment Outcome
Źródło :
Bone Marrow Transplantation, 51(6), 799 - 806. Nature Publishing Group
Bone marrow transplantation, 51(6), 799 - 806. Nature Publishing Group
Tytuł :
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
Autorzy :
Eberhardt, W E E
De Ruysscher, D
Weder, W
Le Péchoux, C
De Leyn, P
Hoffmann, H
Westeel, V
Stahel, R
Felip, E
Peters, S
Pokaż więcej
Temat :
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Bronchoscopy
Carboplatin/administration & dosage
Carcinoma, Non-Small-Cell Lung/diagnosis
Carcinoma, Non-Small-Cell Lung/pathology
Chemotherapy, Adjuvant
Cisplatin/administration & dosage
Disease Management
Endoscopic Ultrasound-Guided Fine Needle Aspiration
Etoposide/administration & dosage
Europe
Humans
Lung/pathology
Lung/radiography
Lung Neoplasms/diagnosis
Lung Neoplasms/pathology
Lymph Nodes/pathology
Mediastinum
Multimodal Imaging
Pneumonectomy
Positron-Emission Tomography
Radiotherapy, Adjuvant
Societies, Medical
Tomography, X-Ray Computed
Vinblastine/administration & dosage
Vinblastine/analogs & derivatives
Clinic for Oncology and Hematology
610 Medicine & health
Źródło :
Eberhardt, W E E; De Ruysscher, D; Weder, W; Le Péchoux, C; De Leyn, P; Hoffmann, H; Westeel, V; Stahel, R; Felip, E; Peters, S (2015). 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 26(8):1573-1588.
Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, vol. 26, no. 8, pp. 1573-1588
Opis pliku :
application/pdf
Tytuł :
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Autorzy :
Thatcher, Nick
Hirsch, Fred R.
Luft, Alexander V.
Szczesna, Aleksandra
Ciuleanu, Tudor E.
Dediu, Mircea
Ramlau, Rodryg
Galiulin, Rinat K.
Balint, Beatrix
Losonczy, Gyorgy
Kazarnowicz, Andrzej
Park, Keunchil
Schumann, Christian
Reck, Martin
Depenbrock, Henrik
Nanda, Shivani
Kruljac-Letunic, Anamarija
Kurek, Raffael
Paz-Ares, Luis
Socinski, Mark A.
Pokaż więcej
Temat :
Adult
Age Factors
Aged
Aged, 80 and over
Antibodies, Monoclonal/administration & dosage
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/pathology
Carcinoma, Squamous Cell/drug therapy/mortality/pathology
Cisplatin/administration & dosage
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Gentamicins/administration & dosage
Humans
Kaplan-Meier Estimate
Lung Neoplasms/drug therapy/mortality/pathology
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Invasiveness/pathology
Neoplasm Staging
Proportional Hazards Models
Risk Assessment
Sex Factors
Survival Analysis
Treatment Outcome
Cardiovascular & respiratory systems [Human health sciences]
Systèmes cardiovasculaire & respiratoire [Sciences de la santé humaine]
Źródło :
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. The Lancet. Oncology, 16(7), 763-74., England. (2015).

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies